Latest Breaking News On - Liver meeting - Page 14 : comparemela.com

Empagliflozin Reduces Liver Fat Content Regardless of T2DM, Study Finds

Findings were presented at The Liver Meeting 2023 from the American Association for the Study of Liver Diseases and showed empagliflozin reduced liver fat content in both patients with T2DM and nondiabetic patients.

United statesLinkedin siham abdelganiSiham abdelganiUniversity of texas at san antonioLiver meetingAmerican associationLiver diseasesSan antonioType 2 diabetes mellitusDiabetes mellitusFatty liverFatty liver diseaseLiver fatHepatic fat

Phase 2 Studies Show OCA-Bezafibrate Achieves Biochemical Remission, ALP Reduction

Topline data from Study 747-213 and a planned interim analysis from Study 747-214 were presented at The Liver Meeting 2023 from the American Association for the Study of Liver Diseases.

United statesMichelle berreyDrug administrationUniversity of miamiAmerican porphyria foundation cynthia levyUniversity of miami hospitalAmerican porphyria foundationCynthia levyLiver meetingAmerican associationLiver diseasesMiami hospitalIntercept announces new phaseShowing significant impactBezafibrate combinationMultiple key biomarkers

Pliant Therapeutics Presentations at The Liver Meeting® 2023 Highlight Bexotegrast, an Inhibitor of αvß6 and αvß1 Integrins, in Primary Sclerosing Cholangitis

Pliant Therapeutics Presentations at The Liver Meeting® 2023 Highlight Bexotegrast, an Inhibitor of αvß6 and αvß1 Integrins, in Primary Sclerosing Cholangitis
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Terry hornerChristopher keenanGideon hirschfieldToronto centre for liver diseaseEuropean medicines agencyAutoimmune liver disease researchPliant therapeutics incCorporate communicationsDrug administrationAmerican associationLiver diseasesLiver meetingChief medical officerTerry horner chairToronto centreLiver disease

Arun Sanyal, MD: Retatrutide and GLP-1 Agonists in MASLD

Sanyal discusses the makeup of retatrutide and its potential for patients with fatty liver disease and comorbid metabolic conditions.

United statesArunj sanyalLiver meetingAmerican associationLiver diseasesGlp 1Fatty liver

Serum Bile Acid Independently Predicts Liver Survival in Alagille Syndrome with Neonatal Cholestasis

A new study from the GALA cohort shows serum bile acid's association with clinical outcomes is relevant in the context of IBAT inhibitor therapy.

United statesC fiorella murillo perezStudy groupGlobal alagille allianceMurillo perezCymabay therapeuticsLiver meetingAmerican associationLiver diseasesAlagille syndromeBile acidRisk factorLiver transplantGala study